MX392410B - Expresión inducida de factor neurotrófico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabólicas. - Google Patents
Expresión inducida de factor neurotrófico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabólicas.Info
- Publication number
- MX392410B MX392410B MX2017009402A MX2017009402A MX392410B MX 392410 B MX392410 B MX 392410B MX 2017009402 A MX2017009402 A MX 2017009402A MX 2017009402 A MX2017009402 A MX 2017009402A MX 392410 B MX392410 B MX 392410B
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- disorders
- syndrome
- developmental
- autoimmune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106365P | 2015-01-22 | 2015-01-22 | |
| PCT/US2016/014312 WO2016118741A1 (en) | 2015-01-22 | 2016-01-21 | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009402A MX2017009402A (es) | 2017-12-04 |
| MX392410B true MX392410B (es) | 2025-03-11 |
Family
ID=55310938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009402A MX392410B (es) | 2015-01-22 | 2016-01-21 | Expresión inducida de factor neurotrófico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabólicas. |
| MX2022005937A MX2022005937A (es) | 2015-01-22 | 2017-07-18 | Expresion inducida de factor neurotrofico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabolicas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005937A MX2022005937A (es) | 2015-01-22 | 2017-07-18 | Expresion inducida de factor neurotrofico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabolicas. |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9763896B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3247340B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6951976B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102690198B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116617195A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016209255B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017015721A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2974092A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2961334T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1247101A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX392410B (cg-RX-API-DMAC7.html) |
| PT (1) | PT3247340T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016118741A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116617195A (zh) | 2015-01-22 | 2023-08-22 | 米托充制药公司 | 脑源性神经营养因子的诱导表达 |
| WO2018129258A1 (en) | 2017-01-06 | 2018-07-12 | Gencia Corporation | Novel phenyl derivatives |
| MX2019009038A (es) * | 2017-01-31 | 2019-12-09 | L Manfredi Paolo | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| EP3641743A2 (en) | 2017-06-23 | 2020-04-29 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20220044150A (ko) * | 2020-09-29 | 2022-04-06 | (주)세포바이오 | Manf를 포함하는 신경정신질환의 예방 또는 치료용 조성물 |
| WO2023205625A2 (en) * | 2022-04-18 | 2023-10-26 | Mitochon Pharmaceuticals, Inc. | 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases |
| WO2025051360A1 (en) * | 2023-09-06 | 2025-03-13 | Instituto de Medicina Molecular João Lobo Antunes | Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1764095A1 (en) * | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| EP2170338A2 (en) * | 2007-07-06 | 2010-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dna-pkcs modulates energy regulation and brain function |
| JP6706204B2 (ja) | 2013-08-30 | 2020-06-03 | イエール ユニバーシティ | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| CN116617195A (zh) * | 2015-01-22 | 2023-08-22 | 米托充制药公司 | 脑源性神经营养因子的诱导表达 |
-
2016
- 2016-01-21 CN CN202211548767.9A patent/CN116617195A/zh active Pending
- 2016-01-21 CA CA2974092A patent/CA2974092A1/en active Pending
- 2016-01-21 KR KR1020177023034A patent/KR102690198B1/ko active Active
- 2016-01-21 EP EP16703409.9A patent/EP3247340B1/en active Active
- 2016-01-21 ES ES16703409T patent/ES2961334T3/es active Active
- 2016-01-21 MX MX2017009402A patent/MX392410B/es unknown
- 2016-01-21 PT PT167034099T patent/PT3247340T/pt unknown
- 2016-01-21 JP JP2017539363A patent/JP6951976B2/ja active Active
- 2016-01-21 AU AU2016209255A patent/AU2016209255B2/en active Active
- 2016-01-21 WO PCT/US2016/014312 patent/WO2016118741A1/en not_active Ceased
- 2016-01-21 US US15/002,531 patent/US9763896B2/en active Active
- 2016-01-21 CN CN201680017379.4A patent/CN107405315A/zh active Pending
- 2016-01-21 BR BR112017015721A patent/BR112017015721A2/pt not_active Application Discontinuation
- 2016-01-21 EP EP23188878.5A patent/EP4306167B1/en active Active
- 2016-01-21 HK HK18106712.4A patent/HK1247101A1/zh unknown
- 2016-11-21 US US15/357,412 patent/US9974755B2/en active Active
-
2017
- 2017-07-18 MX MX2022005937A patent/MX2022005937A/es unknown
- 2017-09-18 US US15/707,239 patent/US10220006B2/en active Active
-
2019
- 2019-01-17 US US16/250,470 patent/US10864173B2/en active Active
-
2020
- 2020-11-09 US US17/093,193 patent/US11717497B2/en active Active
-
2021
- 2021-03-01 JP JP2021031635A patent/JP7440092B2/ja active Active
- 2021-09-27 AU AU2021240120A patent/AU2021240120A1/en not_active Abandoned
-
2022
- 2022-10-03 JP JP2022159466A patent/JP2022173519A/ja active Pending
-
2023
- 2023-06-16 US US18/336,440 patent/US20240156750A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022005937A (es) | Expresion inducida de factor neurotrofico derivado cerebral (bdnf) para tratamiento de enfermedades neuromusculares, neurodegenerativas, autoinmunes, de desarrollo y/o metabolicas. | |
| PH12018502336A1 (en) | Benzazepine derivative, preparation method , pharmaceutical composition and use thereof | |
| MX2022016276A (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EP4164694A4 (en) | ARRDC1-MEDIATED MICROVESICLE-BASED DELIVERY TO THE NERVOUS SYSTEM | |
| WO2018015573A3 (en) | Trem2 cleavage modulators and uses thereof | |
| MX2019002444A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| MX2020002884A (es) | Método y composición neuroprotectora mejorada para tratar afecciones neurológicas. | |
| MX2019007053A (es) | Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas. | |
| EP4414037A3 (en) | Morphinan derivatives for the treatment of opioid delta receptor agonist-related diseases | |
| MX2021003207A (es) | Analogo de dinucleotido ciclico. composicion farmaceutica del mismo y su aplicacion. | |
| NZ709399A (en) | Method of treatment of hypoxia inducible factor (hif)-related conditions | |
| Khatoon et al. | The role of natural products in Alzheimer's and Parkinson's disease | |
| CA3148794A1 (en) | 4-amino-quinolines/-quinazolines that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders | |
| WO2016005962A3 (en) | Stable liquid formulations of cyclophosphamide and processes | |
| MX2016000724A (es) | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. | |
| BR112021019110A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| MX2023008839A (es) | Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales. | |
| BR112019000314A2 (pt) | derivados de etinila | |
| WO2014074761A3 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| IL290434A (en) | Delivery of therapeutic compounds to the central nervous system via olfaction | |
| YIN | Effects of protocatechuic acid on expression of D2DR, iNOS, and TH in striatum and midbrain of Parkinson's disease model mice | |
| WO2016153957A3 (en) | Methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases | |
| ZHANG | Advance in Anticipatory Postural Adjustments for Stroke Patients with Hemiplegia |